Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 19/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 19/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 19/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14891477 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14892124 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14906171 | 0.98 | CYP3A4 (0.61) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL1911217 | 0.98 | CYP3A4 (0.61) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14892772 | 0.93 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14892318 | 0.93 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14892231 | 0.84 | CYP3A4 (0.76) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14891657 | 0.84 | CYP3A4 (0.70) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14892750 | 0.84 | CYP3A4 (0.70) | CYP3A4CYP2D6CYP2C9PIM1PIM3 | |
| SCHEMBL14892971 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2D6CYP2C9PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |